PCSK9 inhibition following outcomes data: what now?
Organized with the participation of Amgen
Vendredi 19 Janvier 2018 12:30-13:30 Maillot room
Lunch debate (organized with the participation of Industry)
12:30 • Michel Farnier
PCSK9: an accelerated development story
12:50 • Denis Angoulvant
Decrease cholesterol further: lower is definitely better
13:10 • Philippe Gabriel Steg
Who would be the priority patients?